Appropriate patient selection and pharmacist-led monitoring were linked to greater adherence to dabigatran among patients with atrial fibrillation at Veterans Health Administration sites, according to a recent study published in JAMA.
The data represents ~3,000 patients who had received the study drug in Phase 3 of GLORIA-AF with up to 2 years follow-up.
American College of Cardiology 2013
At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, leading cardiologists presented that the use of dabigatran following ablation for atrial fibrillation resulted in no major post-procedural complications.
If Tybost is given with atazanavir or darunavir, coadministration with rivaroxaban is not recommended due to a potentially increased bleeding risk.
The primary efficacy outcome was the combined rate of death from a cardiovascular cause, heart attack, stroke due to inadequate blood supply, blood clots or amputation due to cardiovascular disease.
The greatest risk reduction of stroke or systemic embolism was seen with dabigatran 150mg twice daily (odds ratio [OR] 0.65, 95% CI: 0.52-0.81), followed by apixaban 5mg twice daily (OR 0.79, 95% CI: 0.66-0.94).
Study patients were randomized to Pradaxa 150mg twice daily or warfarin (target INR 2-3) and remained on this treatment for the trial duration.
The American College of Chest Physicians has released the latest evidence-based guideline with updated recommendations for appropriate treatment of patients with venous thromboembolism (VTE).
Complete reversal was seen within 4 hours in the majority of patients, as measured by ecarin clotting time (ECT 82%) or diluted thrombin time (dTT 99%). In addition, there was a low late of thrombotic events and no new safety events were reported.
The primary safety endpoint was defined as time to major bleeding events and clinically relevant non-major bleeding events when compared to triple therapy with warfarin.